MRNA vs. PFE: Moderna vs. Pfizer Stock Comparison

November 11, 2026

How do Moderna (MRNA) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Moderna (MRNA) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MRNA is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Company profile comparison for Moderna (MRNA) and Pfizer (PFE)
Profile Item	MRNA	PFE
Name	Moderna Inc.	Pfizer Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	101.48 billion USD	167.52 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	December 7, 2018	June 1, 1972
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MRNA

PFE

GSPC

Moderna (MRNA) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Moderna (MRNA) and Pfizer (PFE). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Moderna (MRNA) and Pfizer (PFE). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
Total Return (1Y)	1,031.66%	28.65%
Total Return (3Y, Annualized)	58.68%	6.41%
Total Return (5Y, Annualized)	3.23%	-3.98%

Risk Profile

Drawdown History

MRNA

PFE

GSPC

Moderna (MRNA) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Moderna (MRNA) and Pfizer (PFE). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
Volatility (1Y, Annualized)	194.88%	21.72%
Beta (5Y)	1.08	0.35
Max Drawdown (5Y)	-93.93%	-58.96%
Avg. Volume (3M)	21.61M	33.67M

Risk-Adjusted Performance

Risk-Return Positioning

MRNA and PFE are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
Sharpe Ratio (1Y)	5.27	1.12
Sortino Ratio (1Y)	20.44	1.73

Profitability

ROE (TTM)

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Pfizer (PFE) reports 4.47%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
MRNA: -39.00%
Q1: -64.05%
Min: -167.77%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max: 109.18%
Q3: 6.23%
PFE: 4.47%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Pfizer (PFE) reports 6.34%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
MRNA: -141.43%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max: 18.05%
PFE: 6.34%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Pfizer (PFE) reports 33.38%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
MRNA: -557.93%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max: 83.12%
PFE: 33.38%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
ROE (TTM)	-39.00%	4.47%
ROA (TTM)	-13.26%	5.59%
Net Margin (TTM)	-141.43%	6.34%
Operating Margin (TTM)	-557.93%	33.38%
Gross Margin (TTM)	-66.02%	74.90%

Growth

Revenue Growth

Both Moderna (MRNA) at -39.92% and Pfizer (PFE) at -1.65% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
Revenue Growth (YoY)	-39.92%	-1.65%
Revenue Growth (3Y CAGR)	-53.30%	-14.80%
EPS Growth (YoY)	--	-3.55%
EPS Growth (3Y CAGR)	--	-37.12%

Financial Strength

Current Ratio (MRQ)

Both Moderna (MRNA) at 2.30 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MRNA: 2.30
Min: 0.10

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
PFE: 1.42
Min: 0.10

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Moderna (MRNA) at 0.19 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max: 1.42
Q3: 0.65
MRNA: 0.19
Median: 0.15
Q1: 0.02
Min: 0.00

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max: 1.42
PFE: 0.71
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
Current Ratio (MRQ)	2.30	1.42
Debt / Equity (MRQ)	0.19	0.71
Net Debt / EBITDA	--	1.97

Dividends

Dividend Yield (TTM)

Moderna (MRNA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE: 7.30%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Moderna (MRNA) pays no dividend (payout 0.00%).

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE: 245.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
Dividend Yield (TTM)	0.00%	7.30%
Dividend Payout Ratio (TTM)	0.00%	245.71%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Pfizer (PFE) trades at 41.99 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
MRNA: --

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max: 85.34
Q3: 43.46
PFE: 41.99
Median: 26.69
Q1: 13.30
Min: 0.07

Moderna (MRNA) vs. Pfizer (PFE): MRNA does not report P/E ratio, so it has no value marker; PFE is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Pfizer (PFE) at 2.63 looks cheap on sales in the lower P/S ratio quartile, while Moderna (MRNA) at 45.55 looks rich in the upper quartile — a clear gap in price per dollar of revenue.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max: 58.18
MRNA: 45.55
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
PFE: 2.63
Min: 0.01

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Pfizer (PFE) at 1.88 is valued about in line with its industry on P/B ratio, while Moderna (MRNA) at 11.58 carries an above-peer premium to book — MRNA is pricier on assets.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max: 13.53
MRNA: 11.58
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max: 13.53
Q3: 6.54
Median: 3.25
PFE: 1.88
Q1: 1.69
Min: -5.59

Moderna (MRNA) vs. Pfizer (PFE): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Moderna (MRNA) and Pfizer (PFE)
Metric	MRNA	PFE
P/E Ratio (TTM)	--	41.99
P/S Ratio (TTM)	45.55	2.63
P/B Ratio (MRQ)	11.58	1.88
Free Cash Flow Yield (TTM)	0.29%	7.76%